Researchers provided comprehensive evidence of the benefits of statin use in elderly patients, addressing longstanding uncertainties. The robust evidence demonstrated that continuous statin therapy ...

DEAR DR. ROACH: A cardiologist recently suggested that I should consider taking a statin because of my “borderline” cholesterol level. So, I took a dive into the details of statin therapy. I learned ...

Dear Dr. Roach: A cardiologist recently suggested that I should consider taking a statin because of my “borderline” cholesterol level. So, I took a dive into the details of statin therapy. I learned ...

The larger risk reductions were not explained by changes in LDL cholesterol, suggesting something else is at play.

Dr. Roach: A cardiologist recently suggested that I should consider taking a statin because of my “borderline” cholesterol level. So, I took a dive into the details of statin therapy. I learned that ...

When patients with paroxysmal nocturnal hemoglobinuria (PNH) received eculizumab, survival rates increased and thromboembolic events/major adverse vascular events (TE/MAVE) decreased. Eculizumab ...

NEW ORLEANS, LA—A PCSK9 inhibitor used on top of lipid-lowering therapy, including a high-intensity statin, significantly cuts the risk of major adverse cardiovascular events compared with placebo ...

Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced Prostate Cancer From Latin America: Challenges and Future Approaches A model of absolute risk ...

SAN DIEGO – A new analysis of a large-scale trial of a novel lipid-lowering agent has shown a particularly large reduction in cardiovascular events in the primary prevention population enrolled in the ...